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Background: Poly lactic-co-glycolic acid (PLGA) based nanoparticles are considered to be a promising drug carrier
in tumor targeting but suffer from the high level of opsonization by reticuloendothelial system due to their
hydrophobic structure. As a result surface modification of these nanoparticles has been widely studied as an
essential step in their development. Among various surface modifications, human serum albumin (HSA) possesses
advantages including small size, hydrophilic surface and accumulation in leaky vasculature of tumors through
passive targeting and a probable active transport into tumor tissues.
Methods: PLGA nanoparticles of docetaxel were prepared by emulsification evaporation method and were surface
conjugated with human serum albumin. Fourier transform infrared spectrum was used to confirm the conjugation
reaction where nuclear magnetic resonance was utilized for conjugation ratio determination. In addition,
transmission electron microscopy showed two different contrast media in conjugated nanoparticles. Furthermore,
cytotoxicity of free docetaxel, unconjugated and conjugated PLGA nanoparticles was studied in HepG2 cells.
Results: Size, zeta potential and drug loading of PLGA nanoparticles were about 199 nm, −11.07 mV, and 4%,
respectively where size, zeta potential and drug loading of conjugated nanoparticles were found to be 204 nm,
−5.6 mV and 3.6% respectively. Conjugated nanoparticles represented a three-phasic release pattern with a 20%
burst effect for docetaxel on the first day. Cytotoxicity experiment showed that the IC50 of HSA conjugated PLGA
nanoparticles (5.4 μg) was significantly lower than both free docetaxel (20.2 μg) and unconjugated PLGA
nanoparticles (6.2 μg).
Conclusion: In conclusion surface modification of PLGA nanoparticles through HSA conjugation results in more
cytotoxicity against tumor cell lines compared with free docetaxel and unconjugated PLGA nanoparticles. Albumin
conjugated PLGA nanoparticles may represent a promising drug delivery system in cancer therapy.
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Polymeric nanoparticles are considered as one of the most
promising carrier systems for cytotoxic drug delivery and
have received a great deal of attention during the recent
years. Poly lactic-co-glycolic acid (PLGA) based nano-
particulate system is one of the most successful and
interesting colloidal systems. PLGA nanoparticles (NPs)
protect the therapeutic agents and increase their stability
and can be used for controlled delivery of therapeutics
with improved pharmacokinetic and pharmacodynamic
profile. Furthermore, PLGA is approved by United States
Food and Drug Administration (FDA) and European
Medicine Agency (EMA) for various drug delivery formu-
lations. However, PLGA NPs, suffer from a significant
limitation due to their high level of opsonization by reticu-
loendothelial system (RES) [1]. To address this negative
aspect, several methods and procedures have been utilized
for surface modification of PLGA NPs in order to produce
PLGA based nanoparticulate systems which are not read-
ily recognized by RES. This goal has been achieved by
PLGA NPs surface coating with more hydrophilic agents
to cover their hydrophobic surface and provide stealth
nanoparticles. Various agents have been used for this pur-
pose including polyethylene glycol (PEG), poloxamers and
chitosan molecules to neutralize or reduce the negative
zeta potential of PLGA NPs and reduce their phagocytosis
by RES [2]. However, surface modified PLGA NPs have
been found to highly localize in liver tissue due to the ri-
gidity of the PLGA core which has triggered many re-
search studies to improve surface modification methods
for achieving better outcomes [3,4].
Among various available agents, human serum albumin
(HSA) seems to be a promising molecule for surface
modification of PLGA NPs. HSA is known to be the most
abundant native protein in human body which has various
advantages including ready availability, biodegradability,
and low toxicity and immunogenicity [5]. HSA has re-
ceived special interest in drug delivery studies due to its
ability for passive targeting through enhanced permeation
and retention (EPR) effect which is related to both “en-
hanced permeation” of macromolecules through the fen-
estrated structure of tumor vasculature in addition to an
“enhanced retention” which is considered to be related to
the lack of effective lymphatic drainage in tumor tissues
[6]. Furthermore it has been postulated that active
targeting of HSA coated nanoparticles occurs through
special albumin receptors on tumor cell membranes [7].
Surface modification of PLGA NPs by grafting protein
molecules has been previously reported and various pro-
teins including transferrin and wheat germ agglutinin
have been coated on the surface of PLGA NPs through
covalent conjugation. The created stealth NPs have suc-
cessfully increased the cellular uptake of PLGA NPs and
have resulted in a greater antiproliferative activity andbetter cytotoxicity in vitro. In addition in vivo experi-
ments have confirmed a higher tumor accumulation for
the above surface coated NPs [8-10]. HSA coating by
non-covalent interactions have also been studied where
protein molecules only saturate the nanoparticles surface
and no covalent linking occurs [11].
Herein, docetaxel (DTX), a cytostatic agent with very
low water solubility was encapsulated in PLGA NPs pro-
duced by a modified emulsification evaporation method
and was subjected to surface modification by HSA mole-
cules through a carbodiimide conjugation reaction. Sur-
face modification created a stealth core shell structure and
was used to reduce the negative charge on PLGA NPs
along with an increase in drug efficiency through passive
targeting. These newly developed fully biodegradable HSA
coated PLGA NPs can increase DTX water solubility and
will eliminate the need for Tween 80 utilization in DTX
formulations which has been taken responsible for many
of DTX injections side effects including hypersensitivity
reactions [12]. The nanoparticles were further evaluated
for their cytotoxic effect in HepG2 cell line. The present
evidences suggest that HSA stealth PLGA NPs may repre-
sent a promising nanoparticulate drug delivery system for
DTX and other anticancer agents.
Methods
Materials
PLGA (50:50, 504H, MW=48 kDa) was purchased from
Boehringer-Ingelheim (Ingelheim, Germany). HSA, 1-
ethy1-3-(3-dimethylaminopropyl) carbodiimide (EDC),
N–hydroxysuccinimide (NHS) and 3-(4,5-dimethyathiazol-
2-yl)-2,5-diphenyltetrazoliumbromide (MTT) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Dulbecco’s modified eagle’s medium (DMEM), fetal bovine
serum (FBS) and penicillin and streptomycin antibiotic
mixture were obtained from Life technologies (grand
Island, NY, USA).Polyvinyl alcohol (PVA) was obtained
from Acros (Geel, Belgium). 2-(N-morpholinoethan-
sulfonicacid) (MES) was purchased from Fluka (St. Louis,
MO, USA). DTX was from Cipla (Mumbai, India). All
other solvents and reagents unless otherwise stated were
from Merck (Darmstadt, Germany).
Preparation of PLGA nanoparticles
PLGA NPs were fabricated using a modified emulsifica-
tion/ evaporation method [12]. Briefly, PVA (0.5% w/w)
was dissolved in deionized water providing the aqueous
phase where MES buffer (50 mmol) was used for pH ad-
justment (pH = 5). In organic phase, PLGA and docetaxel
were dissolved in mixtures with various ratios of acetone
and dichloromethane and the resulting organic phase was
slowly added to the aqueous phase using an ultrasonic
probe (Misonix, USA) equipped with a microtip (power:
11 watt, time: 5 min). During sonication, the whole system
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phase due to evaporation and the mixture was magnetic-
ally stirred overnight. The experiment was conducted with
10% and 20% organic phase to water phase ratio to evalu-
ate the effect of oil: water ratio on the formed
nanoparticles characteristics. Purification of nanoparticles
was achieved by three times centrifugation with a high
speed centrifuge (21,000 g for 30 minutes) at 10°C (Sigma
3 K30, Ostrode, Germany) to remove any extra PVA from
the NPs surface. The isolated NPs were then lyophilized
into a fine cake.
Surface modification of PLGA NPs by HSA conjugation
PLGA NPs were conjugated with HSA through a
carbodiimide coupling reaction. For this purpose, PLGA
carboxylic functional groups were first activated through
exposure with 15 mg EDC and 12 mg NHS for 5 h right
after their preparation in a medium consisting of MES buf-
fer (pH = 5, 50 mmol). The activated NPs were then puri-
fied by three times centrifugation (21,000 g for 30 minutes)
at 10°C to remove any remnants of PVA, EDC and NHS.
The activated PLGA nanoparticles were then exposed
to HSA solution in 40 ml phosphate buffered saline
(PBS, pH = 7.4) with an equimolar concentration in a
dropwise manner and under constant stirring. The con-
jugated NPs were then isolated by a centrifugation step
(15,000 g for 30 minutes) at 10°C and the supernatant
was removed. Conjugated NPs were then subjected to
the lyophilization process for long term storage.
Determination of HSA conjugated PLGA NPs molecular
structure
For determining the number of free carboxylic moieties
in activated PLGA NPs and further calculation of the ac-
tivation ratio a Bruker 500 MHz 1H-NMR system
(Bruker, Germany) was used and the resulting nuclear
magnetic resonance (NMR) spectrum was utilized to
characterize the substitution degree of activated PLGA.
Fourier transform infrared (FT-IR) spectroscopy was
used to characterize the molecular structure of PLGA NPs
conjugated with HSA and to confirm the structural
changes occurred after HSA conjugation. Lyophilized
samples were placed on KBr disks and their FT-IR spectra
were recorded by a Nicolet (Magna IR-550, USA)
spectrophotometer.
NPs characterization and morphology evaluation
PLGA and PLGA NPs conjugated with HSA were fully
characterized and their size, poly dispersity index (PDI)
and zeta potential were determined by dynamic light
scattering (DLS) (Malvern Zetasizer, ZS, Malvern, UK).
To evaluate the particles morphology, PLGA NPs
were coated with gold under vacuum conditions andtheir morphology was evaluated by scanning electron
microscopy (SEM) (FE-SEM, S4160, Hitachi, Japan).
Furthermore, transmission electron microscope (TEM)
(Zeiss EM10C, Carl Zeiss AG, Oberkochen, Germany)
was used to evaluate the surface morphology of PLGA
NPs conjugated with HSA.
Differential scanning calorimetry (DSC) was performed
for PLGA NPs conjugated with HSA in addition to a phys-
ical mixture of PLGA, HSA and DTX with a Mettler DSC
823 unit (Mettler Toledo, Switzerland) and a Julabo
thermocryostate model FT100Y (Julabo labortechnik,
Germany) where Indium was utilized for instrument cali-
bration. The scanning took place between 20 to 200°C
with a thermal scan rate of 10°C per minute.
Determination of DTX concentration, drug loading and
entrapment efficiency in nanoparticles
The extent of DTX loading in PLGA and PLGA NPs con-
jugated with HSA was investigated by a previously pub-
lished method [13]. Briefly, a small amount of PLGA NPs
(2 mg) was dispersed in 2 ml acetonitrile resulting in
PLGA and DTX dissolution in acetonitrile medium. In the
next step methanol was added to the above mixture and
resulted in PLGA precipitation. This solution only
contained DTX and was injected to high pressure liquid
chromatography (HPLC) (Knauer apparatus model K-
1001 Wellchrome (Berlin, Germany) equipped with a
PDA K-2700 ultraviolet Detector (Knauer, Berlin,
Germany). A C18 column (internal diameter: 0.46 cm,
length: 25 cm, pore size: 5 μm, ODS 3-MZ, Germany) was
used as stationary phase and acetonitrile: water mixture
(65: 35) was used as the mobile phase. The analysis was
performed in 230 nm wavelength at 25°C and DTX con-
centration was evaluated accordingly. Furthermore, “drug
loading” which is calculated as the ratio between DTX
(expressed as μg) and the PLGA NPs (expressed as mg) in
addition to “entrapment efficiency” or the percent of drug
loaded in PLGA nanoparticles to the initial amount of
DTX were determined.
DTX release from PLGA nanoparticles
Dialysis technique was used to evaluate drug release from
PLGA NPs [14]. A dialysis tube (molecular weight cut-off:
8 kDa) containing 2 mg of nanoparticles suspended in
5 ml PBS (pH = 7.4) was dipped in a medium consisting of
20 ml PBS (pH =7.4) containing 0.1% Tween 80 and was
continuously stirred on a shaker incubator for over 14 days
at 37°C. At selected time intervals, 15 mL of the medium
was removed and the medium was replenished with
freshly prepared PBS. The aliquots were then exposed to
dichloromethane for liquid-liquid extraction of DTX. The
extraction procedure was repeated three times and the
extracted organic phase was evaporated and the remnants
were dissolved in 200 μl acetonitrile and were subjected to
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percentage of the cumulative amount of drug release.
In vitro cytotoxicity of DTX encapsulated NPs
HepG2 (Human hepatocellular carcinoma) cells were
obtained from Pasteur Institute of Iran (Tehran, Iran) and
were cultivated and maintained in DMEM growth media
supplemented with 10% FBS and 1% penicillin strepto-
mycin antibiotic mixture. The cells were incubated at 37°C
in a humidified atmosphere with 5% CO2 and the culture
media was exchanged every other day. Cells were seeded in
96 wells with a density of 1 × 104 cells per well and were in-
cubated for 24 h to allow cellular attachment. Cells were
then treated with different concentrations of free DTX,
PLGA NPs and PLGA NPs conjugated with HSA for 96
hand were then exposed to 20 μL of MTT reagent (5 mg/
mL per well) for an additional 4 h. The culture media was
then discarded and 200 μL dimethylsulfoxide was added to
each well to dissolve the formed formazan crystals. Optical
density was then measured at 570 nm with a 660 nm back-
ground using a microplate reader (Anthos 2020; Anthos
Labtec Instruments, Wals, Austria). Each experiment was
performed in triplicate and cellular viability was expressed
as the percentage of viable cells to control. IC50 was calcu-
lated from the cell viability data as the drug concentration
in which cell growth was inhibited by 50%. Furthermore
similar MTT assays were performed with drug free PLGA
NPs and conjugated PLGA NPs with HSA to assess any in-
trinsic carrier toxicity.
Results and Discussion
PLGA nanoparticles preparation and characterization
PLGA nanoparticles were prepared by a modified emulsifi-
cation evaporation method (Figure 1). In this method theFigure 1 PLGA and conjugated PLGA nanoparticles with HSA formatiorganic phase solution containing DTX and PLGA provides
the oil phase (O) and PVA aqueous solution serves as the
water phase (W) in an O/W emulsion. Physical sonication
induction reduces the size of nano droplets in this emul-
sion. The particulate characteristics of prepared PLGA NPs
in addition to their drug loading and entrapment efficiency
are shown in Table 1. As it is observed PLGA NPs had an
average size of 180 to 221 nm and were monodispersed as
confirmed by their PDI amounts which was less than or
equal to 0.23. Nanoparticles drug loading was achieved by
drug incorporation into PLGA NPs during the production
process and a maximum 5.35% drug loading with about
48% entrapment efficiency was achieved. The formed NPs
carried a negatively charged zeta potential of about -11mv.
Size is the most important and effective parameter in
determining the cellular uptake and biological functions
of colloidal systems where a reduced size will usually re-
sult in significantly better uptake of nanoparticles by
tumor cells [15]. It has been demonstrated that emulsion
fabrication is the most critical step during the prepar-
ation of nanoparticles where the size of emulsion drop-
lets is directly relevant to the final nanoparticles size
[16,17]. Various factors may affect the size of PLGA NPs
including the stabilizer type and the oil phase solvent
mixture composition.
The oil phase solvent mixture here was composed of
various ratios of dichloromethane and acetone. As shown
in Figure 2A, nanoparticles size decreased as a result of re-
ducing the acetone to dichloromethane ratio in the oil
phase mixture where the smallest size was achieved by a
40:60 (acetone: dichloromethane) ratio. This may be due
to a decrease in the interfacial tension between the oil
phase and aqueous phase with increasing the portion of
acetone in the oil phase mixture. It has been reported thaton process.
Table 1 PLGA nanoparticles and PLGA nanoparticles conjugated with HSA characteristics (DCM: dichloromethane,
O: oil phase, W: water phase, HSA: human serum albumin, PLGA: Poly (lactic-co-glycolic acid), PDI: polydispersity
index and EE: entrapment efficiency)
Sample Acetone: DCM O:W ratio (%) HSA:PLGA Size (nm) PDI Zeta potential (mv) E.E (%) Loading (μg/mg)
1 2.5:97.5 20 - 221 ± 25 0.23 ± 0.02 −13.48 ± 1.8 18.5 ± 2.1 2.06 ± 0.18
2 10:90 20 - 195 ± 19 0.15 ± 0.01 −11.71 ± 2.1 25.2 ± 1.8 2.8 ± 0.41
3 20:80 20 - 188 ± 28 0.14 ± 0.01 −15.32 ± 2.3 9.3 ± 1.6 1.0 ± 0.2
4 40:60 20 - 180 ± 29 0.20 ± 0.02 −11.13 ± 1.9 6.2 ± 1.1 0.7 ± 0.05
5 5:95 10 - 204 ± 20 0.15 ± 0.02 −11.52 ± 1.5 13.5 ± 1.1 1.5 ± 0.1
6 10:90 10 - 199 ± 22 0.17 ± 0.01 −11.07 ± 1.8 48.2 ± 2.3 5.35 ± 0.33
7 20:80 10 - 189 ± 19 0.18 ± 0.02 −9.83 ± 1.3 9.46 ± 1.4 1.05 ± 0.07
8 30:70 10 - 186 ± 22 0.16 ± 0.01 −11.08 ± 1.4 2.8 ± 0.7 0.3 ± 0.03
9 40:60 10 - 180 ± 21 0.20 ± 0.02 −11.02 ± 1.7 7.6 ± 1.5 0.85 ± 0.1
10 10:90 10 50:50 204 ± 15 0.14 ± 0.01 −5.6 ± 0.21 33.7 ± 2.6 3.62 ± 0.42
11 10:90 10 75:25 221 ± 24 0.17 ± 0.01 −5.45 ± 0.24 34.2 ± 2.1 3.53 ± 0.37
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aqueous phases are not in equilibrium and the acetone
concentration is not homogenous at the interface of oil
and water phases. Acetone diffuses through the higher vis-
cosity oil phase resulting in an acetone concentration gra-
dient which creates some perturbation and turbulence in
the interface of the two phases. This perturbation further
results in a larger interface area between the oil droplets
and aqueous medium and creates extremely fine nano
droplets which result in the formation of small sized
nanoparticles. The interfacial tension decrease between
the oil and water phases due to the presence of acetone in
the organic solvent mixture in addition to acetone passive
diffusion from nano droplets and the subsequent spontan-
eous mixing will result in PLGA NPs formation with a
much smaller size [17].
Besides the size of NPs, loading and entrapment effi-
ciency are also affected by acetone to dichloromethane ra-
tio. As it is observed in Figure 2B, loading is decreasedFigure 2 The effect of acetone to dichloromethane ratio on PLGA nanwith increasing the acetone: dichloromethane ratio from
10:90 to 40:60. In addition entrapment efficiency shows
the same trend and a decrease in this parameter is ob-
served with increasing acetone to dichloromethane ratio.
DTX has poor water solubility and favors the organic
phase during oil in water emulsion preparation. This
higher drug affinity to the oil core results in a higher drug
loading and better entrapment efficiency [18]. However
when acetone to dichloromethane ratio is very low, both
loading and entrapment efficiency are significantly de-
creased which may be related to the high DTX solubility
in acetone solutions [19]. On the other hand when acetone
to dichloromethane ratio is increased, some of the drug
molecules dissolved in the oil core may disperse out along
with acetone. This results in some sort of drug leak and
will decrease the drug loading [17].
In addition to the oil phase composition, the ratio of oil to
water is another factor which may impact the evaporation
phase and nanoparticles formation process. Decreasing theoparticles size (A) and drug loading (B).
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nanoparticles size along with a slight increase in their en-
trapment efficiency and drug loading (Table 1). It has been
postulated that when the aqueous phase volume is increased
in relation to oil phase, the droplets external energy which is
the cause of droplets breakage is distributed in a higher vol-
ume and a lower droplet breakage and an elevated particle
size will be achieved [20,21].
Nanoparticles stabilization and protection of the drop-
lets is another important step in the emulsification process
which is achieved by addition of surfactant molecules.
These surfactants prevent drops coalescence and result in
a better size. In this study 0.5% PVA was used as a
stabilizer to create a cover between organic and aqueous
phases interface and provide effective stabilization [22,23].
PLGA NPs size and morphology was further evaluated
by SEM microscopy which showed roughly spherical
particles (Figure 3). It is noteworthy that NPs showed a
larger size when evaluated by DLS compared to SEM
images which may be due to the swelling of particles
when dispersed in the aqueous medium [16].Characterization of PLGA nanoparticles conjugated with
HSA
HSA was conjugated to carboxylic functional groups on
PLGA structure through a carbodiimide meditated coup-
ling reaction Figure 1). FT-IR spectra of PLGA, HSA, their
physical mixture and PLGA NPs conjugated with HSA are
shown in Figure 4. As it can be seen, free PLGA ester and
acid bonds absorption peaks can be observed in 1760 (cm-1)
and 1713 (cm-1). In free HSA the amide bond stretch re-
gion was observed in 1650 (cm-1). When HSA conjugated
PLGA nanoparticles spectrum was evaluated, 1760 (cm-1),
1713 (cm-1) and 1650 (cm-1) absorption peaks were ob-
served which confirms the presence of both PLGA and
HSA structures in the conjugated NPs.Figure 3 Poly (lactic-co-glycolic acid) (PLGA) nanoparticles morpholog
times magnification.Activated PLGA NPs structure was further evaluated
by its 1H NMR spectra to predict the ratio of covalently
conjugated carboxylic functional groups on PLGA NPs.
For this purpose area under the curve of NHS peak at
2.0 ppm was compared with area under the curve of
PLGA peaks at 5.4, 4.9 and 1.5 ppm in activated PLGA
NMR spectra. It was found that about 30% of PLGA car-
boxylic acid moieties were involved in PLGA activation
reaction where about 70% of carboxylic functional
groups remained free. This suggests a 30% conjugation
ratio between PLGA and HSA.
To further evaluate HSA conjugated PLGA nanoparticles,
size and zeta potential of these particles were evaluated and
were compared with unconjugated PLGA NPs (Table 1).
As it is observed, the size of PLGA NPs conjugated with
HSA was slightly increased in comparison to PLGA NPs.
Zeta potential which is another important nanoparticle
characteristic and can influence particle stability and cell
adhesion was also measured in PLGA NPs conjugated
with HSA [24]. As shown in Table 1, the zeta potential
of PLGA NPs conjugated with HSA showed a negative
zeta potential, which was smaller than that of PLGA
NPs (−11.07 ± 1.8 mV vs. -5.6 ± 0.21 mV). This decrease
in negative zeta potential is probably due to the involve-
ment of carboxylic functional groups on PLGA NPs in
amide bond formation with amino moieties on lysine
amino acids in HSA primary structure [25].
Entrapment efficiency and loading of PLGA NPs and
PLGA NPs conjugated with HSA are shown in Table 1. As
it is shown, the entrapment efficiency and drug loading in
PLGA NPs conjugated with HSA were slightly less than
PLGA NPs.
PLGA NPs morphology was evaluated by TEM im-
aging (Figure 5). As it is observed PLGA NPs were al-
most spherical with a size of about 200 nm where HSA
conjugated NPs showed a slightly larger size. PLGA NPs
were uniform but a notable outer layer was observed iny acquired by scanning electron microscopy with 15,000
Figure 4 FT-IR spectrum of HSA, PLGA, their physical mixture and PLGA NPs conjugated with HSA (PLGA major absorption peaks are
observed in 1760 (cm-1) and 1713 (cm-1) where HSA major absorption peak comes in 1650 (cm-1)).
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room structure on NPs surface which is in accordance
with the predicted core-shell structure and may be able to
prevent PLGA NPs opsonization more effectively [26].
Drug polymer mixtures may exist in various forms and
structures for example amorphous or crystalline drug in
combination with an amorphous or crystalline polymer
[27]. DSC was utilized here to examine the thermal transi-
tions in PLGA NPs and PLGA NPs conjugated with HSA.
Figure 6 shows DSC thermograms of PLGA, DTX,
HSA, PLGA NPs and PLGA NPs conjugated with HSA in
addition to a physical mixture of PLGA, DTX and HSA.
As it can be seen, PLGA has an endothermic glassy transi-
tion temperature around 50°C. Glassy transition endother-
mic process for HSA conjugated NPs was observed at
about 60°C. In the physical mixture thermogram a peak isFigure 5 Appearance of A) PLGA nanoparticle and B) PLGA nanoparti
microscopy with 50,000 times magnification (Conjugation has occurre
clearly observe).observed in 160°C which stands for DTX melting point
peak in its crystalline form. This peak is not observed in
PLGA NPs and PLGA NPs conjugated with HSA which
suggests an absence of crystallinity and an amorphous
structure for DTX molecules in these NPs [28,29].
DTX release pattern from PLGA and HSA conjugated
PLGA NPs
Various factors may affect drug release behavior from
PLGA NPs including the polymer type and composition
and drug-polymer interactions. In vitro drug release pat-
tern from PLGA and PLGA NPs conjugated with HSA is
shown as the cumulative percentage of release in Figure 7.
DTX release from PLGA NPs followed a bi-phasic pattern.
As shown in Figure 7, a burst release occurs within 10 h
when roughly 40% of the drug was released from thecle conjugated with HSA acquired by transmission electron
d in the surface of PLGA nanoparticles where phase contrast is
Figure 6 DSC thermograms of PLGA, HSA, DTX and DTX loaded in PLGA NP conjugated with HSA (Peaks of PLGA, HSA, and DTX was
observed at 48°C, 60°C and 160°C. In DTX encapsulated HSA-PLGA nanoparticles, PLGA peak was observed at 48°C, HSA peak was observed at
60°C and no peak was observed at 160°C indicating the amorphous structure of DTX in this nanoparticulate formulation).
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rate within 12 days. This initial burst release may be re-
lated to the portion of DTX molecules which are adsorbed
on nanoparticle’s surface and the diffusion controlled drug
dissolution of drug molecules at nanoparticles and
medium interface [30]. In addition the release of DTX
molecules which are encapsulated near the surface of
PLGA NPs may also contribute in this initial burst release.
The slower second phase is related to the entrapped DTX
inside the polymeric NPs.Figure 7 DTX release pattern from PLGA NPs and PLGA NPs conjugat
release of DTX occurred in the first 10 hours. The drug was then released s
20% burst release of DTX occurred within 24 hours and the overall releaseThe release profile of DTX from PLGA NPs conjugated
with HSA exhibited a three-phasic pattern (Figure 7). 20%
initial burst release occurred at the first day and in the
next 8 days 75% of DTX was released. The rest of the drug
was eventually released within 4 days. Comparing the re-
lease pattern of these two nanoparticles demonstrated that
the release rate of DTX from conjugated NPs was slower
and followed a three phasic pattern including an initial
burst phase, a second release phase and a much slower
final drug release phase.ed with HSA in PBS medium (pH = 7.4). In PLGA NPs, 40% burst
lowly within 12 days (green line); In PLGA NPs conjugated with HSA,
rate was much slower compared to PLGA NPs (blue line).
Figure 8 Cell viability in HepG2 cell line in exposure to free DTX, DTX encapsulated PLGA NPs and DTX encapsulated HSA-PLG NPs
with various concentrations against Hep-G2 assessed by MTT assay (n = 3).
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molecules has resulted in a reduced initial burst where
only 20% of drug is released during the first 24 h from
HSA conjugated NPs in comparison to around 60% in
unconjugated NPs. This lower burst effect is probably
due to a decrease in the amount of drug which is
adsorbed on the surface of conjugated NPs [9].In vitro cytotoxicity assay
To assess the cellular cytotoxicity of PLGA NPs and
PLGA NPs conjugated with HSA, HepG2 cell line was
used. HepG2 cell line has been recognized as a suitable
model for cytotoxicity evaluating studies [31]. Following
72 h of exposure to both unconjugated and conjugated
NPs, cell viability was assessed by MTT assay and IC50
values of free DTX and its formulations were estimated
from the results as presented in Figure 8. The IC50 of free
DTX, PLGA NPs and PLGA NPs conjugated with HSA
were 20.2 ± 0.28, 6.2 ± 0.23 and 5.4 ± 0.21 μg respectively
after 72 h incubation with the cell line (n = 3). These re-
sults may be explained by drug release pattern of various
PLGA particulate formulations and their degradation pro-
files. When DTX is encapsulated in PLGA or PLGA NPs
conjugated with HSA a higher DTX concentration may be
delivered to the intracellular space which may be the re-
sult of the small size of nanoparticles and the passive
targeting of macromolecules due to EPR effect. As a result
a better efficacy and a lower IC50 is observed for HSA
conjugated with PLGA NPs [32].
It should be mentioned that in PLGA NPs conjugated
with HSA, the outer layer, HSA, creates a stealth surface
which reduces NPs interaction (both interactions be-
tween NPs and interaction between cells and NPs) [33].It is noteworthy that no cellular cytotoxic effect was ob-
served when drug free PLGA NPs and drug free PLGA
NPs conjugated with HSA were exposed to HepG2 cell line
which confirms these carriers safety.Conclusions
In this study surface modified PLGA NPs with HSA
were developed to prepare a novel drug delivery particu-
late system which may preferentially target tumor tissues
through passive targeting. Specific features of HSA such
as its biocompatibility and accumulation in inflamed and
tumor tissues make it a good candidate for surface
functionalization of carriers. Herein, PLGA NPs conju-
gated with HSA were developed and fully characterized.
The newly developed NPs had an acceptable size and
zeta potential and showed promising results in cell cul-
ture investigation where a lower IC50 was observed for
the conjugated nanoparticles in comparison with free
DTX and unconjugated PLGA NPs. It seems that surface
modification of PLGA NPs with human serum albumin
may represent a promising approach for nanoparticulate
delivery system for cytostatic agent delivery.Competing interests
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